MCID: MGK001
MIFTS: 58

Megakaryocytic Leukemia

Categories: Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Megakaryocytic Leukemia

MalaCards integrated aliases for Megakaryocytic Leukemia:

Name: Megakaryocytic Leukemia 38 12 14
Acute Megakaryoblastic Leukemia 12 50 56
Acute Megakaryocytic Leukemias 12 69
Acute Megakaryocytic Leukemia 50 56
Acute Myeloid Leukemia M7 50 56
Aml M7 50 56
Amkl 50 56
Acute Megakaryoblastic Leukaemia, Fab M7 12
Acute Megakaryoblastic Leukemia, Fab M7 12
Acute Myeloblastic Leukemia Type 7 50
Leukemia, Megakaryoblastic, Acute 42
Megakaryoblastic Leukemia, Acute 13
Megakaryoblastic Leukemia Acute 52
Leukemia, Myelocytic, Acute 69
Megakaryocytic Myelosis 12
Thrombocytic Leukaemia 12

Characteristics:

Orphanet epidemiological data:

56
acute megakaryoblastic leukemia
Inheritance: Not applicable; Age of onset: Childhood;

Classifications:



External Ids:

Disease Ontology 12 DOID:8761
ICD10 33 C94.2 C94.20
ICD9CM 35 207.2
MeSH 42 D007947
NCIt 47 C3170
Orphanet 56 ORPHA518
UMLS via Orphanet 70 C0023462
ICD10 via Orphanet 34 C94.2
UMLS 69 C0023462

Summaries for Megakaryocytic Leukemia

NIH Rare Diseases : 50 the following summary is from orphanet, a european reference portal for information on rare diseases and orphan drugs.orpha number: 518disease definitionacute megakaryoblastic leukemia (amkl) is a form of acute myeloid leukemia (aml; see this term) that occurs predominantly in childhood and particularly in children with down syndrome (ds-amkl). nonspecific symptoms may be irritability, weakness, and dizziness while specific symptoms include pallor, fever, mucocutaneous bleeding, hepatosplenomegaly, neurological manifestations and rarely lymphadenopathy. acute panmyelosis with myelofibrosis (see this term)may also be associated with amkl. in contrast to ds-amkl (around 80 % survival), non-ds-amkl is an aml subgroup associated with poor prognosis.visit the orphanet disease page for more resources. last updated: 11/10/2015

MalaCards based summary : Megakaryocytic Leukemia, also known as acute megakaryoblastic leukemia, is related to acute megakaryoblastic leukemia in down syndrome and acute megakaryoblastic leukemia without down syndrome, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Megakaryocytic Leukemia is GATA1 (GATA Binding Protein 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Cyclophosphamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Increased cell death HMECs cells and Decreased viability in HMC1.1 cells

Disease Ontology : 12 A leukemia that derives from blood-forming tissue in which megakaryocytes proliferate in the bone marrow and circulate in the blood in large numbers.

Wikipedia : 72 Acute megakaryoblastic leukemia (AMKL) is a form of leukemia where a majority of the blasts are... more...

Related Diseases for Megakaryocytic Leukemia

Diseases related to Megakaryocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 71)
id Related Disease Score Top Affiliating Genes
1 acute megakaryoblastic leukemia in down syndrome 12.2
2 acute megakaryoblastic leukemia without down syndrome 12.1
3 acquired cystic disease-associated renal cell carcinoma 10.8 MKL1 RBM15
4 leukemia 10.7
5 sideroblastic anemia 10.6 CSF2 IL3
6 pontocerebellar hypoplasia type 2b 10.5 GATA1 IL3 JAK2
7 dic in newborn 10.4 CSF2 IL3 KITLG
8 postsynaptic congenital myasthenic syndromes 10.4 IL3 JAK2 RUNX1
9 primary systemic mycosis 10.4 CBS CSF2
10 benign mammary dysplasia 10.4 CSF2 IL3 KITLG
11 hepatosplenic t-cell lymphoma 10.3 GATA1 MPO
12 single ventricular heart 10.1 CSF2 IL3 JAK2 KITLG
13 down syndrome 10.1
14 germ cells tumors 10.1
15 peroxisome biogenesis disorder 5a 10.0 GATA1 IL3 MPO RUNX1
16 thrombocytopenia, congenital amegakaryocytic 9.9 IL3 THPO
17 amyotrophic lateral sclerosis 15, with or without frontotemporal dementia 9.9 GATA1 THPO
18 acute myocardial infarction 9.9 CSF2 RUNX1 TP53
19 acute lymphoblastic leukemia, childhood 9.9 IL3 JAK2 MPO RUNX1
20 cheek mucosa cancer 9.8 CSF2 IL3 MPO RUNX1
21 prostatic cyst 9.8 IL11 ITGA2B THPO
22 sarcoma 9.8
23 pulmonary hypertension 9.8
24 acute leukemia 9.8
25 hematopoietic stem cell transplantation 9.8
26 hypoxia 9.8
27 hepatitis 9.8
28 prostate cancer, hereditary, x-linked 1 9.8 KITLG PTEN TP53
29 thrombocytopenic purpura, autoimmune 9.8 IL11 ITGA2B THPO
30 cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1 9.8 IL3 JAK2 THPO
31 spinal polio 9.8 ITGA2B KITLG THPO
32 breast myoepithelial neoplasm 9.8 PTEN TP53
33 nephronophthisis 15 9.8 CSF2 JAK2 JAK3 RUNX1
34 thrombocytopenia-absent radius syndrome 9.7 GATA1 JAK2 THPO
35 myeloproliferative neoplasm 9.7 ITGA2B PF4 RUNX1 THPO
36 preeclampsia/eclampsia 3 9.7 KITLG MPO RUNX1 TP53
37 acquired central diabetes insipidus 9.7
38 essential thrombocythemia 9.7
39 teratoma 9.7
40 cerebritis 9.7
41 pneumonia 9.7
42 malignant teratoma 9.7
43 mediastinitis 9.7
44 vasculitis 9.7
45 myeloid sarcoma 9.7
46 beckwith-wiedemann syndrome 9.7
47 myeloid leukemia 9.7
48 diabetes insipidus 9.7
49 periostitis 9.7
50 trisomy 1q 9.7

Comorbidity relations with Megakaryocytic Leukemia via Phenotypic Disease Network (PDN):


Acquired Thrombocytopenia Deficiency Anemia
Neutropenia

Graphical network of the top 20 diseases related to Megakaryocytic Leukemia:



Diseases related to Megakaryocytic Leukemia

Symptoms & Phenotypes for Megakaryocytic Leukemia

UMLS symptoms related to Megakaryocytic Leukemia:


angina pectoris, chest pain, edema

GenomeRNAi Phenotypes related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 9.1 IL11 IL3 JAK2 PTEN TP53 CSF2
2 Decreased viability in HMC1.1 cells GR00105-A-0 8.96 JAK3 LYN

MGI Mouse Phenotypes related to Megakaryocytic Leukemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 GATA1 IL6R ITGA2B JAK2 JAK3 KITLG
2 cellular MP:0005384 10.26 CSF2 GATA1 IL6R ITGA2B JAK2 JAK3
3 homeostasis/metabolism MP:0005376 10.24 CSF2 GATA1 IL6R ITGA2B JAK2 KITLG
4 immune system MP:0005387 10.2 TRIB1 CSF2 GATA1 IL6R ITGA2B JAK2
5 endocrine/exocrine gland MP:0005379 10.09 IL6R JAK2 JAK3 KITLG MKL1 PTEN
6 embryo MP:0005380 10.06 PTEN RUNX1 TP53 CSF2 GATA1 ITGA2B
7 integument MP:0010771 9.91 CSF2 GATA1 JAK2 KITLG LYN MKL1
8 liver/biliary system MP:0005370 9.81 GATA1 IL6R JAK2 KITLG LYN PTEN
9 mortality/aging MP:0010768 9.8 MKL1 MPO PTEN RBM15 RUNX1 TP53
10 neoplasm MP:0002006 9.23 CSF2 IL6R JAK2 KITLG PTEN RBM15

Drugs & Therapeutics for Megakaryocytic Leukemia

Drugs for Megakaryocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 217)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
2
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
3 Thiotepa Approved Phase 4,Phase 2,Phase 1 52-24-4 5453
4 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
6 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
7 Antilymphocyte Serum Phase 4,Phase 2,Phase 1
8
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
9
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
10
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
11
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
12
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
13
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
14
Amsacrine Approved Phase 3 51264-14-3 2179
15
Idarubicin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 58957-92-9 42890
16
Thioguanine Approved Phase 3,Phase 1 154-42-7 2723601
17
Mesna Approved Phase 3 3375-50-6 598
18
Oprelvekin Approved, Investigational Phase 2, Phase 3 145941-26-0
19
Clofarabine Approved, Investigational Phase 2, Phase 3, Phase 1 123318-82-1 119182
20
Asparaginase Approved Phase 3,Phase 2,Phase 1 9015-68-3
21
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
22
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
23
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754 657311
24
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
25
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
26
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
27
Azacitidine Approved, Investigational Phase 2, Phase 3, Phase 1 320-67-2 9444
28
Melphalan Approved Phase 2, Phase 3, Phase 1 148-82-3 4053 460612
29
Hydroxyurea Approved Phase 3 127-07-1 3657
30
Carmustine Approved Phase 3 154-93-8 2578
31
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
32
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
33
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
34
Fluconazole Approved Phase 3 86386-73-4 3365
35
Cyproheptadine Approved Phase 3 129-03-3 2913
36
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
37
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538
38
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
39
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
40
Butyric Acid Experimental Phase 3 107-92-6 264
41
tipifarnib Investigational Phase 2, Phase 3,Phase 1 192185-72-1 159324
42 Staurosporine Experimental Phase 3,Phase 1 62996-74-1
43 Vaccines Phase 3
44 Gemtuzumab Phase 2, Phase 3, Phase 1
45 Analgesics Phase 3,Phase 2,Phase 1
46 Antibodies Phase 3,Phase 2
47 Antibodies, Monoclonal Phase 3,Phase 2
48 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
49 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
50 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 190)

id Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
3 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
4 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
5 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
6 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
7 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
8 Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia Unknown status NCT02241031 Phase 2, Phase 3 thrombopoietin (TPO) and interleukin-11
9 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
10 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
11 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
12 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
13 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
14 Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
15 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
16 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
17 Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
18 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
19 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
20 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
21 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
22 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3 cytarabine;laromustine
23 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
24 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
25 High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
26 Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
27 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
28 Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Active, not recruiting NCT01307579 Phase 3 caspofungin acetate;fluconazole
29 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
30 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
31 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
32 Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
33 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Unknown status NCT02038153 Phase 1, Phase 2 Lenalidomide
34 Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
35 Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Unknown status NCT00425477 Phase 2 bexarotene
36 VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
37 Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00006084 Phase 2
38 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
39 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
40 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
41 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
42 Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT01020734 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate
43 Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Completed NCT00372619 Phase 1, Phase 2 clofarabine;cytarabine;methotrexate
44 Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome Completed NCT00002547 Phase 2 busulfan;cyclophosphamide;cyclosporine;cytarabine;methotrexate
45 Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003396 Phase 2 cyclophosphamide;melphalan
46 Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer Completed NCT00003335 Phase 2 busulfan;cyclosporine;melphalan;methylprednisolone
47 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
48 Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Completed NCT01870596 Phase 2 Cytarabine;CHK1 Inhibitor SCH 900776
49 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Completed NCT01361464 Phase 2 Tipifarnib
50 A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia Completed NCT00463385 Phase 2 Pomalidomide;Prednisone;Placebo to pomalidomide;Placebo to prednisone

Search NIH Clinical Center for Megakaryocytic Leukemia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Megakaryocytic Leukemia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia, megakaryoblastic, acute

Genetic Tests for Megakaryocytic Leukemia

Anatomical Context for Megakaryocytic Leukemia

MalaCards organs/tissues related to Megakaryocytic Leukemia:

39
Myeloid, Bone, Bone Marrow, Monocytes, Liver

Publications for Megakaryocytic Leukemia

Articles related to Megakaryocytic Leukemia:

(show top 50) (show all 115)
id Title Authors Year
1
CCND1-BCL2 Gene Network: A direct target of Amifostine in human acute megakaryocytic leukemia cells. ( 27762064 )
2016
2
Megakaryocytic leukemia 1 directs a histone h3 lysine 4 methyltransferase complex to regulate hypoxic pulmonary hypertension. ( 25646298 )
2015
3
Acute megakaryocytic leukemia: What have we learned. ( 26228843 )
2015
4
Extramedullary Tumor of Cerebral Falx: An Unusual Presentation of Acute Megakaryocytic Leukemia. ( 24663070 )
2014
5
Relapse of acute megakaryocytic leukemia as hepatic myeloid sarcoma after allogeneic haploidentical hematopoietic stem cell transplantation. ( 24916785 )
2014
6
Acute megakaryocytic leukemia is associated with worse outcomes than other types of acute myeloid leukemia. ( 25498456 )
2014
7
Megakaryocytic leukemia 1 (MKL1) regulates hypoxia induced pulmonary hypertension in rats. ( 24647044 )
2014
8
Hemophagocytosis in acute megakaryocytic leukemia: hemophagocytosis or emperipolesis? ( 23823115 )
2013
9
Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia. ( 23874683 )
2013
10
Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia. ( 23533276 )
2013
11
Case study interpretation-New Orleans: case 1. Extramedullary acute megakaryocytic leukemia. ( 23283835 )
2013
12
Megakaryocytic leukemia 1 (MKL1) ties the epigenetic machinery to hypoxia-induced transactivation of endothelin-1. ( 23625963 )
2013
13
Hematopoietic overexpression of the transcription factor Erg induces lymphoid and erythro-megakaryocytic leukemia. ( 22936051 )
2012
14
Identification of TRIB1 R107L gain-of-function mutation in human acute megakaryocytic leukemia. ( 22294728 )
2012
15
Congenital acute megakaryocytic leukemia. ( 22557786 )
2011
16
A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy. ( 22110660 )
2011
17
A rare case of GATA1 negative chemoresistant acute megakaryocytic leukemia in an 8-month-old infant with trisomy 21. ( 20108342 )
2010
18
Acute megakaryocytic leukemia (AMKL,FAB;M7) with Beckwith-Wiedemann syndrome. ( 20589645 )
2010
19
Hypercalcemia in pediatric acute megakaryocytic leukemia: case report and review of the literature. ( 19415024 )
2009
20
Unbalanced chromosome 1 abnormalities leading to partial trisomy 1q in four infants with Down syndrome and acute megakaryocytic leukemia. ( 19228396 )
2009
21
RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. ( 19638627 )
2009
22
The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy. ( 18094719 )
2008
23
Massive periosteal reaction a presenting feature of acute megakaryocytic leukemia. ( 18045316 )
2007
24
Chronic megakaryocytic leukemia, misnamed chronic idiopathic myelofibrosis, has neoplastic not hyperplastic megakaryocytopoiesis. ( 17916755 )
2007
25
Segregation of megakaryocytic or erythroid cells from a megakaryocytic leukemia cell line (JAS-R) by adhesion during culture. ( 17383723 )
2007
26
Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome. ( 17988992 )
2007
27
Histologic and molecular characterizations of megakaryocytic leukemia in mice. ( 16219351 )
2006
28
[The role of GATA1 mutation in acute megakaryocytic leukemia]. ( 17176883 )
2006
29
Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. ( 16249385 )
2006
30
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. ( 16123215 )
2006
31
Is it chronic idiopathic myelofibrosis, myelofibrosis with myeloid metaplasia, chronic megakaryocytic-granulocytic myelosis, or chronic megakaryocytic leukemia? Further thoughts on the nosology of the clonal myeloid disorders. ( 15902283 )
2005
32
Inhibition by Rho-kinase and protein kinase C of myosin phosphatase is involved in thrombin-induced shape change of megakaryocytic leukemia cell line UT-7/TPO. ( 15567063 )
2005
33
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. ( 16037387 )
2005
34
Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). ( 15191953 )
2005
35
GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. ( 15687366 )
2005
36
Arsenic trioxide mediates intrinsic and extrinsic pathways of apoptosis and cell cycle arrest in acute megakaryocytic leukemia. ( 16010437 )
2005
37
Interleukin-11 as an osteoprotegerin-inducing factor in culture medium of blastic cells from a patient with acute megakaryocytic leukemia complicated with osteosclerosis. ( 15307108 )
2004
38
Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. ( 15317736 )
2004
39
Severe megakaryocytic dysplasia in a case of myelodysplasia progressing to acute megakaryocytic leukemia presenting with dic(1;16)(q21;p13.3) and t(1;22)(p13;q13). ( 14553955 )
2003
40
Transcriptional regulation of the cystathionine-beta -synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines. ( 12393509 )
2003
41
AML1 overexpression and/or mutations should be checked in trisomy 21 patients with megakaryocytic leukemia. ( 12835737 )
2003
42
Acute megakaryocytic leukemia presenting as hypercalcemia with skeletal lytic lesions. ( 12225399 )
2002
43
Acute megakaryocytic leukemia in essential thrombocythemia: an unusual evolution? ( 12366715 )
2002
44
Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia. ( 11344311 )
2001
45
Criteria for diagnosis of acute megakaryocytic leukemia. ( 11263442 )
2001
46
Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. ( 11001891 )
2000
47
The effects of arsenic trioxide (As2O3) on human megakaryocytic leukemia cell lines. With a comparison of its effects on other cell lineages. ( 10811458 )
2000
48
The role of p53 in megakaryocyte differentiation and the megakaryocytic leukemias of Down syndrome. ( 10616523 )
2000
49
Simultaneous detection of platelet-associated antigen and platelet peroxidase on buffy coat cells from bone marrow in two patients with pediatric acute megakaryocytic leukemia. ( 10524465 )
1999
50
Hepatic involvement by congenital megakaryocytic leukemia in a neonate: sonographic features. ( 10511179 )
1999

Variations for Megakaryocytic Leukemia

ClinVar genetic disease variations for Megakaryocytic Leukemia:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 GATA1 NM_002049.3(GATA1): c.154_173dup20 (p.Ala59Glnfs) duplication Pathogenic rs398124628 GRCh37 Chromosome X, 48649670: 48649689
2 PTEN NM_000314.6(PTEN): c.406T> C (p.Cys136Arg) single nucleotide variant Pathogenic rs786201044 GRCh37 Chromosome 10, 89692922: 89692922
3 TP53 NM_000546.5(TP53): c.636delT (p.Arg213Aspfs) deletion Pathogenic rs864309495 GRCh38 Chromosome 17, 7674895: 7674895

Copy number variations for Megakaryocytic Leukemia from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 158678 21 35304204 35704075 Loss RUNX1 Acute megakaryoblastic leukaemia

Expression for Megakaryocytic Leukemia

Search GEO for disease gene expression data for Megakaryocytic Leukemia.

Pathways for Megakaryocytic Leukemia

Pathways related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

(show all 35)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 CSF2 IL11 IL3 IL6R ITGA2B JAK2
2
Show member pathways
13.81 CSF2 IL11 IL3 IL6R ITGA2B JAK2
3
Show member pathways
13.62 CSF2 IL11 IL3 IL6R JAK2 JAK3
4
Show member pathways
13.51 IL11 IL3 IL6R ITGA2B JAK2 JAK3
5
Show member pathways
13.29 CSF2 IL11 IL3 IL6R ITGA2B JAK2
6
Show member pathways
13.29 CSF2 IL11 IL3 IL6R ITGA2B JAK2
7
Show member pathways
13.25 CSF2 IL11 IL3 IL6R JAK2 KITLG
8
Show member pathways
13.21 CSF2 GATA1 IL3 ITGA2B JAK2 JAK3
9
Show member pathways
13.03 IL3 ITGA2B KITLG LYN PTEN THPO
10 12.64 ITGA2B KITLG PTEN RUNX1 TP53
11 12.63 IL3 IL6R ITGA2B JAK2 JAK3 KITLG
12
Show member pathways
12.46 CSF2 IL3 IL6R JAK2 JAK3 MPO
13
Show member pathways
12.34 JAK2 JAK3 PTEN TP53
14 12.21 CSF2 IL3 MPO RUNX1 TP53
15
Show member pathways
12.15 IL3 JAK2 KITLG LYN PTEN
16
Show member pathways
12.11 CSF2 IL3 JAK2 JAK3 LYN
17
Show member pathways
12.1 CSF2 IL11 IL3 IL6R JAK2 JAK3
18 12.1 GATA1 IL3 JAK2 JAK3 KITLG LYN
19 12.01 GATA1 IL11 IL3 KITLG RUNX1 THPO
20 11.97 IL6R JAK2 JAK3 TP53
21 11.92 IL3 IL6R PTEN TP53
22 11.87 CSF2 IL11 IL3 ITGA2B KITLG MPO
23 11.86 IL3 IL6R JAK2 JAK3
24
Show member pathways
11.85 CSF2 IL6R JAK2 JAK3
25
Show member pathways
11.84 IL6R JAK2 JAK3
26 11.76 ITGA2B PTEN TP53
27 11.72 GATA1 KITLG MPO
28
Show member pathways
11.58 IL11 IL6R JAK2
29 11.5 ITGA2B JAK2 LYN
30 11.49 IL11 IL3 IL6R KITLG
31 11.31 CSF2 GATA1 IL3 ITGA2B KITLG RUNX1
32 11.26 CSF2 IL11 IL3
33 11.18 CSF2 IL11 IL3 PF4
34 11.15 CSF2 IL11 IL3 IL6R ITGA2B KITLG
35 10.87 KITLG LYN

GO Terms for Megakaryocytic Leukemia

Cellular components related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 CSF2 IL11 IL3 IL6R KITLG MPO
2 extrinsic component of cytoplasmic side of plasma membrane GO:0031234 8.8 JAK2 JAK3 LYN

Biological processes related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

(show all 28)
id Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.88 JAK2 MPO PF4 TRIB1
2 MAPK cascade GO:0000165 9.88 CSF2 IL3 JAK2 JAK3 KITLG
3 cytokine-mediated signaling pathway GO:0019221 9.85 IL3 IL6R JAK2 PF4
4 peptidyl-tyrosine phosphorylation GO:0018108 9.77 CSF2 IL3 JAK2 JAK3 LYN
5 positive regulation of cell proliferation GO:0008284 9.76 CSF2 IL11 IL3 IL6R JAK2 KITLG
6 peptidyl-tyrosine autophosphorylation GO:0038083 9.75 JAK2 JAK3 LYN
7 positive regulation of DNA replication GO:0045740 9.71 CSF2 IL3 KITLG
8 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.69 CSF2 GATA1 PF4
9 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.64 CSF2 PF4
10 positive regulation of leukocyte migration GO:0002687 9.63 ITGA2B KITLG
11 positive regulation of macrophage differentiation GO:0045651 9.62 PF4 TRIB1
12 enzyme linked receptor protein signaling pathway GO:0007167 9.62 JAK2 JAK3
13 tyrosine phosphorylation of STAT protein GO:0007260 9.61 JAK2 JAK3
14 embryonic hemopoiesis GO:0035162 9.61 GATA1 IL3 KITLG
15 megakaryocyte differentiation GO:0030219 9.59 GATA1 IL11
16 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.58 JAK2 JAK3 LYN
17 STAT protein import into nucleus GO:0007262 9.57 JAK2 JAK3
18 positive regulation of hematopoietic stem cell proliferation GO:1902035 9.56 KITLG THPO
19 erythrocyte differentiation GO:0030218 9.56 GATA1 JAK2 JAK3 LYN
20 negative regulation of cytolysis GO:0045918 9.52 CSF2 PF4
21 dendritic cell differentiation GO:0097028 9.5 CSF2 GATA1 LYN
22 regulation of B cell apoptotic process GO:0002902 9.49 LYN PTEN
23 positive regulation of mast cell proliferation GO:0070668 9.46 KITLG LYN
24 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.35 CSF2 IL3 IL6R JAK2 LYN
25 regulation of B cell receptor signaling pathway GO:0050855 9.3 LYN
26 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.23 GATA1 IL11 IL3 IL6R JAK2 KITLG
27 negative regulation of apoptotic process GO:0043066 10.03 GATA1 KITLG MPO PTEN TP53
28 negative regulation of cell proliferation GO:0008285 10 GATA1 JAK2 LYN PTEN TP53

Molecular functions related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.77 CBS IL6R LYN PTEN TP53
2 protein tyrosine kinase activity GO:0004713 9.65 CSF2 IL3 JAK2 JAK3 LYN
3 growth factor activity GO:0008083 9.55 CSF2 IL11 IL3 KITLG THPO
4 non-membrane spanning protein tyrosine kinase activity GO:0004715 9.5 JAK2 JAK3 LYN
5 platelet-derived growth factor receptor binding GO:0005161 9.43 LYN PTEN
6 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.35 CSF2 IL3 JAK2 JAK3 KITLG
7 cytokine activity GO:0005125 9.1 CSF2 IL11 IL3 KITLG PF4 THPO
8 protein binding GO:0005515 10.33 CBS CSF2 GATA1 IL11 IL6R ITGA2B

Sources for Megakaryocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....